Condition Lookup
Category:
Bone and Mineral Metabolism Disorders
Number of Conditions: 6
Postmenopausal Osteoporosis
Specialty: Diabetes and Endocrinology
Category: Bone and Mineral Metabolism Disorders
Sub-category: Osteoporosis
Symptoms:
fractures from minor trauma (e.g., hip, wrist, vertebral); back pain; loss of height; stooped posture
Root Cause:
Decreased estrogen levels after menopause lead to accelerated bone resorption, reducing bone density and increasing fracture risk.
How it's Diagnosed: videos
Bone Mineral Density (BMD) testing using dual-energy X-ray absorptiometry (DEXA), clinical assessment of risk factors, and evaluation for fragility fractures.
Treatment:
Lifestyle modifications (calcium and vitamin D supplementation, weight-bearing exercises), anti-resorptive medications (e.g., bisphosphonates), and anabolic therapies (e.g., teriparatide).
Medications:
Bisphosphonates (e.g., alendronate , risedronate ) to inhibit bone resorption; selective estrogen receptor modulators (e.g., raloxifene ) for estrogen mimicry; denosumab (RANK ligand inhibitor); teriparatide (parathyroid hormone analog for bone building); and calcitonin .
Prevalence:
How common the health condition is within a specific population.
Affects approximately 20% of postmenopausal women globally, with higher prevalence in individuals of European and Asian descent.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Advanced age, early menopause, low body weight, family history of osteoporosis, smoking, excessive alcohol intake, physical inactivity, and inadequate calcium/vitamin D intake.
Prognosis:
The expected outcome or course of the condition over time.
With early diagnosis and treatment, fracture risk can be significantly reduced, and quality of life preserved. Without treatment, progressive bone loss may lead to frequent fractures and disability.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Fractures, particularly of the hip and spine, which can lead to chronic pain, loss of independence, and increased mortality.
Glucocorticoid-Induced Osteoporosis
Specialty: Diabetes and Endocrinology
Category: Bone and Mineral Metabolism Disorders
Sub-category: Osteoporosis
Symptoms:
bone pain; increased susceptibility to fractures; height loss; muscle weakness
Root Cause:
Chronic glucocorticoid use reduces osteoblast activity and increases bone resorption, resulting in decreased bone formation and loss of bone mass.
How it's Diagnosed: videos
Assessment of bone density via DEXA scan, history of long-term glucocorticoid use, and clinical evaluation of fracture risk.
Treatment:
Minimizing glucocorticoid dosage when possible, supplementation with calcium and vitamin D, use of bisphosphonates or denosumab to reduce bone resorption, and anabolic therapies such as teriparatide for severe cases.
Medications:
Bisphosphonates like alendronate or zoledronic acid to reduce bone turnover; denosumab (a RANKL inhibitor) to prevent resorption; and teriparatide (a parathyroid hormone analog) to stimulate bone formation. Calcium and vitamin D are essential for all patients.
Prevalence:
How common the health condition is within a specific population.
Up to 30-50% of patients on long-term glucocorticoids develop significant bone loss; higher rates in older adults and postmenopausal women.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Long-term use of glucocorticoids, low body weight, advanced age, previous fractures, smoking, alcohol consumption, and low calcium/vitamin D intake.
Prognosis:
The expected outcome or course of the condition over time.
Early intervention can prevent fractures, but untreated cases carry a high risk of recurrent fractures and long-term disability.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Fragility fractures, particularly in the spine and ribs, leading to chronic pain, deformity, and impaired mobility.
Secondary Causes of Osteoporosis (e.g., Hyperthyroidism)
Specialty: Diabetes and Endocrinology
Category: Bone and Mineral Metabolism Disorders
Sub-category: Osteoporosis
Symptoms:
bone pain; fractures from minimal trauma; muscle weakness; height loss; fatigue
Root Cause:
Secondary osteoporosis results from an underlying medical condition (e.g., excess thyroid hormone in hyperthyroidism), which accelerates bone resorption and decreases bone strength.
How it's Diagnosed: videos
Identification of the underlying condition through blood tests (e.g., thyroid hormone levels, parathyroid hormone levels), DEXA scan to measure bone density, and evaluation for fragility fractures.
Treatment:
Treating the underlying cause (e.g., controlling hyperthyroidism with antithyroid medications or surgery), calcium and vitamin D supplementation, and using anti-resorptive agents like bisphosphonates if indicated.
Medications:
Bisphosphonates for bone preservation; treatment for the underlying cause (e.g., methimazole for hyperthyroidism or cinacalcet for hyperparathyroidism). Calcium and vitamin D are adjunct therapies.
Prevalence:
How common the health condition is within a specific population.
Varies depending on the underlying condition; hyperthyroidism-induced bone loss is common in individuals with untreated or poorly managed thyroid disease.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Presence of underlying medical conditions like hyperthyroidism, hyperparathyroidism, malabsorption syndromes, and chronic inflammatory diseases.
Prognosis:
The expected outcome or course of the condition over time.
Prognosis improves significantly with successful management of the underlying condition and preventive measures for bone health.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Increased fracture risk, chronic pain, spinal deformities, and reduced quality of life.
Phosphate Disorders
Specialty: Diabetes and Endocrinology
Category: Bone and Mineral Metabolism Disorders
Sub-category: Electrolyte Imbalance
Symptoms:
muscle weakness; bone pain; fatigue; confusion; seizures; irregular heartbeats
Root Cause:
Abnormal phosphate levels in the blood, either hypophosphatemia (low phosphate) or hyperphosphatemia (high phosphate), affecting cellular and skeletal functions.
How it's Diagnosed: videos
Blood tests to measure serum phosphate, calcium, and PTH levels; urine tests for phosphate excretion; assessment of vitamin D status and kidney function.
Treatment:
Treated by addressing the underlying cause, with hypophosphatemia managed using oral or intravenous phosphate supplementation, and hyperphosphatemia treated with phosphate binders, dietary restrictions, and managing associated conditions like kidney disease.
Medications:
Hypophosphatemia - Oral phosphate supplements (e.g., potassium phosphate or sodium phosphate) or intravenous phosphate for severe cases. Hyperphosphatemia - Managed with phosphate binders such as calcium acetate, calcium carbonate, sevelamer , lanthanum carbonate, or aluminum hydroxide, often alongside dietary phosphate restrictions and treatments for underlying conditions like chronic kidney disease.
Prevalence:
How common the health condition is within a specific population.
Varies widely; hypophosphatemia is common in hospitalized patients and those with malnutrition, while hyperphosphatemia often occurs in individuals with chronic kidney disease (CKD).
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Kidney disease, malnutrition, alcohol dependency, vitamin D deficiency or excess, certain medications (e.g., diuretics or antacids).
Prognosis:
The expected outcome or course of the condition over time.
Good with early recognition and management. Chronic untreated phosphate disorders can lead to long-term complications.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
For hypophosphatemia
Hyperphosphatemia
Specialty: Diabetes and Endocrinology
Category: Bone and Mineral Metabolism Disorders
Symptoms:
muscle cramps; tetany; calcifications in soft tissues; itching; joint pain
Root Cause:
Excess phosphate in the blood due to decreased renal excretion (e.g., kidney disease), excessive intake, or cellular release.
How it's Diagnosed: videos
Serum phosphate levels >4.5 mg/dL, often accompanied by elevated serum PTH, calcium, and creatinine in secondary hyperparathyroidism.
Treatment:
Reducing dietary phosphate, phosphate binders (e.g., sevelamer, lanthanum carbonate), and treating underlying conditions like chronic kidney disease.
Medications:
Phosphate binders like sevelamer , calcium acetate, and lanthanum carbonate are used to lower phosphate levels in the blood.
Prevalence:
How common the health condition is within a specific population.
Common in chronic kidney disease patients, with prevalence up to 70% in advanced stages.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Chronic kidney disease, excessive phosphate intake (e.g., supplements or processed foods), hypoparathyroidism, and certain genetic disorders.
Prognosis:
The expected outcome or course of the condition over time.
Treatable with dietary and medical management, but persistent hyperphosphatemia increases cardiovascular and mortality risks.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Vascular calcifications, cardiovascular disease, and secondary hyperparathyroidism.
Hypophosphatemia
Specialty: Diabetes and Endocrinology
Category: Bone and Mineral Metabolism Disorders
Symptoms:
muscle weakness; bone pain; rhabdomyolysis; confusion; seizures
Root Cause:
Deficiency of phosphate in the blood due to inadequate intake, excessive loss, or intracellular shifts (e.g., refeeding syndrome).
How it's Diagnosed: videos
Serum phosphate levels <2.5 mg/dL, alongside clinical evaluation and identifying underlying causes.
Treatment:
Oral or intravenous phosphate supplementation depending on severity, and addressing the underlying cause (e.g., vitamin D deficiency or refeeding syndrome).
Medications:
Oral phosphate supplements (e.g., sodium phosphate, potassium phosphate) or intravenous phosphate in severe cases. Vitamin D (calcitriol ) may also be used to aid phosphate absorption.
Prevalence:
How common the health condition is within a specific population.
Common in critically ill patients, alcoholics, or those with refeeding syndrome; prevalence varies depending on underlying conditions.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Chronic alcoholism, malnutrition, vitamin D deficiency, refeeding syndrome, and hyperparathyroidism.
Prognosis:
The expected outcome or course of the condition over time.
Excellent with prompt treatment; prolonged or severe cases can result in complications like muscle breakdown or cardiac issues.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Rhabdomyolysis, respiratory failure, hemolysis, and impaired immune function.